[Skip to Content]
[Skip to Content Landing]
Citations 0
February 9, 2011

KRAS Genotypes and Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

JAMA. 2011;305(6):564-566. doi:10.1001/jama.2011.85

To the Editor: According to the retrospective analysis of KRAS genotypes and outcome after treatment with cetuximab in patients with chemotherapy-refractory metastatic colon cancer, Dr De Roock and colleagues reported that patients with KRAS codon p.G13D mutations who received cetuximab compared with best supportive care experienced longer progression-free and overall survival.1 In contrast, patients with other KRAS mutations did not appear to benefit from cetuximab. Previously, any type of KRAS mutation indicated a lack of effect of anti-epidermal growth factor receptor monoclonal antibody therapy.1